Skip to main content
. 2017 Feb 15;8(15):25097–25106. doi: 10.18632/oncotarget.15341

Figure 5. Gal-1 knockdown enhanced sensitivity to PTX and ADR by reducing P-glycoprotein expression through inhibiting the Raf-1/AP-1 signaling pathway.

Figure 5

A. The levels of P-gp, p-Raf-1 (Ser338), Raf-1, p-c-Jun (Ser73), c-Jun and c-Fos in MCF-7/PTX cells with Raf-1 siRNA1, Raf-1 siRNA2 or si-control transfection were detected by western blot. β-actin was used for normalization. B. The levels of P-gp, p-Raf-1 (Ser338), Raf-1, p-c-Jun (Ser73), c-Jun and c-Fos in MCF-7/ADR cells with GW5074 (5 and 10 μM) treatment were detected by western blot. β-actin was used for normalization. C. and E. With 15 nM PTX treatment, the relative cell viability and apoptosis in MCF-7/PTX cells cotransfected Raf-1 siRNA1 with pcDNA 3.1-MDR1 were assessed by MTT assay and flow cytometry. D. and F. With 300 nM ADR treatment, the relative cell viability and apoptosis in MCF-7/ADR cells with 10 μM GW5074 treatment and pcDNA 3.1-MDR1 transfection were assessed by MTT assay and flow cytometry. Data are presented as mean ± SD. *P < 0.05, ***P < 0.001.